Figure 4: Algorithm of management of hepatitis C positive patients after surveillance. Individuals who have elevated liver enzymes, detectable hepatitis C virus RNA in the serum or abnormal liver biopsy, such as moderate degrees of inflammation or fibrosis, should be treated. Current therapy for genotype 1 infection is a combination of interferon, ribavirin and a protease inhibitor or nucleotide polymerase inhibitor sofosbuvir. Dual therapy with interferon and ribavirin or sofosbuvir with ribavirin is applied for treatment of genotype 2 and 3. Patients with genotype 4 should be treated with combination of sofosbuvir, interferon and ribavirin (http://www.who.int/hiv/pub/hepatitis/hepatitis-cguidelines/en/). HCV RNA level should be checked after 12 weeks and therapy will be continued if HCV RNA become undetectable or >2 logs below baseline. Viral RNA level should be checked again after stopping therapy for sustained virological response.